Comparison · NCT05576051-70d6ed5d
Tofacitinib Initiators Combination vs Tofacitinib Initiators Monotherapy: Number of Participants With Modified American College of Rheumatology 20% (mACR20) at 6 Months for Tofacitinib Monotherapy vs Tofacitinib With MTX
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tofacitinib Initiators Combination vs Tofacitinib Initiators Monotherapy: Number of Participants With Modified American College of Rheumatology 20% (mACR20) at 6 Months for Tofacitinib Monotherapy vs Tofacitinib With MTX. Trial comparisons, record NCT05576051-70d6ed5d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05576051-70d6ed5d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.211 | 0.14 | 0.306 | wilson | |
| Risk in group 2 | 0.207 | 0.148 | 0.283 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0037 | -0.101 | 0.116 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.606 | 1.71 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.531 | 1.97 | log | |
| Number needed to treat, for one more participant with the outcome on Tofacitinib Initiators Combination than on Tofacitinib Initiators Monotherapy | 270 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tofacitinib Initiators Combination | Participants diagnosed with RA, enrolled in Corrona RA registry who initiated Tofacitinib initiators treatment with combination of MTX were included in this reporting group. Data was collected for this study from 4-Jun-2015. | 19 | 90 | OG000 |
| Group 2 | Tofacitinib Initiators Monotherapy | Participants diagnosed with RA, enrolled in Corrona RA registry who initiated Tofacitinib initiators monotherapy treatment were included in this reporting group. Data was collected for this study from 4-Jun-2015. | 28 | 135 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Modified American College of Rheumatology 20% (mACR20) at 6 Months for Tofacitinib Monotherapy vs Tofacitinib With MTX
- Description
mACR20 response: \>= 20 percent (%) improvement in tender and swollen joint count and 20% improvement in 2 of the following 4 criteria: 1) participant assessment of pain (scored from 0 to 100, higher scores indicated worsened pain) ; 2) participant global assessment of disease activity (scored from 0 to 100, higher scores indicated worsened condition); 3) physician global assessment of disease activity (scored from 0 to 100, higher scores indicated worsened condition); 4) self-assessed disability index of the mHAQ (scored from 0 to 3, higher scores indicated worsened function).
- Time frame
- At month 6 follow up visit
- Population
Analysis population included all eligible participants whose medical records were retrieved and observed in this study. Here, Overall number of Participants Analyzed (N) signifies number of participants evaluable for this outcome measure.
Source ClinicalTrials.gov
Trial
- Title
To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.
- NCT number
- NCT05576051
- Phases
- Conditions
- Rheumatoid Arthritis
- Interventions
- patterns of use of combination therapy and monotherapy
- Lead sponsor
- Pfizer
- Results first posted
- 2025-12-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05576051?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05576051-70d6ed5d